Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic, and ultimately fatal diffuse parenchymal lung disease. The molecular mechanisms of fibrosis in IPF patients are not fully understood and there is a lack of effective treatments. For decades, different types of drugs such as immunosuppressants and antioxidants have been tested, usually with unsuccessful results. Although […]
Category: Nintedanib
Plasticity towards Rigidity: A Macrophage Conundrum in
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat Toby M. Maher1,2* and Mary E. Strek3 Correspondence: t.maher@rbht.nhs.uk1National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London,SW3 6NP, UK2Fibrosis Research Group, National Heart and Lung Institute, Imperial College, Cale Street, London SW3 6LY, UKFull list of […]
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Idiopathic Pulmonary Fibrosis (IPF): An Overview Shaney L. Barratt 1,2,*, Andrew Creamer 1, Conal Hayton 3 and Nazia Chaudhuri 3 1 Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol BS10 5NB, UK;andrew.creamer@nbt.nhs.uk2 Academic Respiratory Unit, University of Bristol, Bristol BS16 1QY, UK3 North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, […]